Bivalirudin for anticoagulation in mechanical aortic valve replacement and heparin-induced thrombocytopenia

Heparin-induced thrombocytopenia (HIT) is a potentially serious syndrome. Since there are some alternatives to treatment with heparin in patients who develop HIT, the decision as to which to use should be based on renal and hepatic function, drug availability and the available monitoring resources....

Full description

Saved in:
Bibliographic Details
Published inBlood coagulation & fibrinolysis Vol. 17; no. 4; p. 331
Main Authors Klein, Moti, Tomer, Aaron, Swartz, Andre, Koyffman, Leonid, Weksler, Natan
Format Journal Article
LanguageEnglish
Published England 01.06.2006
Subjects
Anticoagulants - administration & dosage
Aortic Valve - transplantation
Fatal Outcome
Female
Follow-Up Studies
Heart Valve Prosthesis
Heparin - adverse effects
Hirudins - administration & dosage
Humans
Middle Aged
Peptide Fragments - administration & dosage
Platelet Count
Recombinant Proteins - administration & dosage
Syndrome
Thrombocytopenia - complications
Thrombocytopenia - drug therapy
Online AccessGet more information

Cover

More Information
Summary:Heparin-induced thrombocytopenia (HIT) is a potentially serious syndrome. Since there are some alternatives to treatment with heparin in patients who develop HIT, the decision as to which to use should be based on renal and hepatic function, drug availability and the available monitoring resources. We report a patient who received heparin for mechanical aortic valve replacement. Her clinical course was complicated by HIT, which was treated initially by danaparoid. The syndrome progressed with new thrombotic complications, and eventually was treated successfully by bivalirudin (Angiomax; Medison Pharma Ltd, Petach Tikva, Israel) for 9 days. We propose that treatment with bivalirudin for several days is a safe and effective alternative to heparin therapy in patients who develop HIT.
ISSN:0957-5235
1473-5733
DOI:10.1097/01.mbc.0000224857.73119.97